Vivus to sell MUSE assets to Sweden's Meda in $23.5 million deal

California, USA-based Vivus. (Nasdaq: VVUS) says that it has entered into an asset purchase agreement with Swedish drugmaker Meda AB (MEDAA: SS) for MUSE, transurethral alprostadil, for the treatment of erectile dysfunction (ED), for around $23.5 million.

Under the deal, Meda will acquire the MUSE assets including the US and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey. As part of the transaction, the existing Vivus employees that are MUSE dedicated, including the field sales force, are expected to join Meda. Vivus will retain all of the liabilities associated with the pre-closing operations of the MUSE business.

Deal will allow Vivus to focus on Qnexa and avanafil